Relay Therapeutics (RLAY) Assets Average (2020 - 2026)
Relay Therapeutics (RLAY) posted quarterly Assets Average of $660.5 million for Q1 2026, down 20.93% year-over-year from $835.3 million in Q1 2025, and up 2.29% quarter-over-quarter from $645.7 million in Q4 2025.
Relay Therapeutics (RLAY) Assets Average (2020 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Assets Average for 7 consecutive years, with $660.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 20.93% year-over-year to $660.5 million; the TTM figure through Mar 2026 stood at $660.5 million (down 20.93% YoY), while the FY2025 annual figure was $746.3 million, down 12.98% from the prior year.
- Assets Average climbed to $660.5 million in Q1 2026 per RLAY's latest filing, from $645.7 million in the prior quarter.
- Across five years, Assets Average topped out at $1.1 billion in Q4 2022 and bottomed at $645.7 million in Q4 2025.
- Historically, Assets Average has averaged $879.3 million across 5 years, with a median of $875.5 million in 2023.
- Annual changes were most pronounced in 2022 — Assets Average jumped 155348.56% — and 2025, when it decreased 28.32%.
- Relay Therapeutics' Assets Average stood at $1.1 billion in 2022, then declined by 22.81% to $875.5 million in 2023, then increased by 2.88% to $900.7 million in 2024, then fell by 28.32% to $645.7 million in 2025, then climbed by 2.29% to $660.5 million in 2026.
- Business Quant data shows RLAY's Assets Average at $660.5 million in Q1 2026, $645.7 million in Q4 2025, and $699.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 833.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 833.54 Mn |
| Mar 31, 2026 | 660.47 Mn |
| Dec 31, 2025 | 645.67 Mn |
| Sep 30, 2025 | 699.42 Mn |
| Jun 30, 2025 | 764.10 Mn |
| Mar 31, 2025 | 835.33 Mn |
| Dec 31, 2024 | 900.71 Mn |
| Sep 30, 2024 | 851.33 Mn |
| Jun 30, 2024 | 807.00 Mn |
| Mar 31, 2024 | 842.71 Mn |
| Dec 31, 2023 | 875.47 Mn |
| Sep 30, 2023 | 934.49 Mn |
| Jun 30, 2023 | 999.79 Mn |
| Mar 31, 2023 | 1.07 Bn |
| Dec 31, 2022 | 1.13 Bn |
| Sep 30, 2022 | 1.03 Bn |
| Jun 30, 2022 | 919.65 Mn |
| Mar 31, 2022 | 979.16 Mn |
| Dec 31, 2021 | 504.55 Mn |
| Sep 30, 2021 | 662,000.00 |